Chugai Pharmaceutical Co., Ltd.

OTCPK:CHGC.Y Stock Report

Market Cap: US$69.4b

Chugai Pharmaceutical Management

Management criteria checks 4/4

Chugai Pharmaceutical's CEO is Osamu Okuda, appointed in Mar 2020, has a tenure of 6.5 years. total yearly compensation is ¥441.00M, comprised of 31.1% salary and 68.9% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth $9.40M. The average tenure of the management team and the board of directors is 5.7 years and 3.5 years respectively.

Key information

Osamu Okuda

Chief executive officer

JP¥441.0m

Total compensation

CEO salary percentage31.07%
CEO tenure6.5yrs
CEO ownership0.01%
Management average tenure5.7yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Osamu Okuda's remuneration changed compared to Chugai Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

JP¥471b

Mar 31 2026n/an/a

JP¥452b

Dec 31 2025JP¥441mJP¥137m

JP¥434b

Sep 30 2025n/an/a

JP¥397b

Jun 30 2025n/an/a

JP¥395b

Mar 31 2025n/an/a

JP¥410b

Dec 31 2024JP¥422mJP¥137m

JP¥387b

Sep 30 2024n/an/a

JP¥387b

Jun 30 2024n/an/a

JP¥355b

Mar 31 2024n/an/a

JP¥326b

Dec 31 2023JP¥375mJP¥119m

JP¥325b

Sep 30 2023n/an/a

JP¥337b

Jun 30 2023n/an/a

JP¥327b

Mar 31 2023n/an/a

JP¥316b

Dec 31 2022JP¥298mJP¥108m

JP¥374b

Sep 30 2022n/an/a

JP¥371b

Jun 30 2022n/an/a

JP¥389b

Mar 31 2022n/an/a

JP¥387b

Dec 31 2021JP¥252mJP¥85m

JP¥303b

Sep 30 2021n/an/a

JP¥256b

Jun 30 2021n/an/a

JP¥231b

Mar 31 2021n/an/a

JP¥211b

Dec 31 2020JP¥84mJP¥40m

JP¥215b

Compensation vs Market: Osamu's total compensation ($USD2.87M) is below average for companies of similar size in the US market ($USD14.74M).

Compensation vs Earnings: Osamu's compensation has been consistent with company performance over the past year.

CEO

Osamu Okuda (63 yo)

6.5yrs
Tenure
JP¥441,000,000
Compensation

Dr. Osamu Okuda serves as Representative Director and President at Chugai Pharmaceutical Co., Ltd. since March 30, 2020 and its Chief Executive Officer since March 23, 2021. He serves as Chairman at Chugai...

Leadership Team

NamePositionTenureCompensationOwnership
Osamu Okuda
President6.5yrsJP¥441.00m0.014%
$ 9.4m
Iwaaki Taniguchi
Senior Executive Officer2.5yrsno data0.00061%
$ 423.0k
Toshiya Sasai
Executive of Investor Relations Group & Corporate Communications Departmentno datano datano data
Junichi Takano
Head of Marketing & Sales Divisionno datano datano data
Shinji Hidaka
Executive Vice President2.7yrsno datano data
Tetsuya Yamaguchi
Executive Vice President6.7yrsno datano data
Yoshiyuki Yano
Executive Vice Presidentno datano datano data
Kosuke Iijima
Head of PHC Solution Departmentno datano datano data
Tomoyuki Igawa
VP & Head of Research Divisionno datano datano data
Kaori Ouchi
Executive Vice Presidentno datano datano data
Nobuya Ishii
Head of Science & Technology Intelligence Dept.no datano datano data
Shinya Takuma
VP & Head of Manufacturing Technology Division5.7yrsno datano data
5.7yrs
Average Tenure

Experienced Management: CHGC.Y's management team is seasoned and experienced (5.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Osamu Okuda
President6.5yrsJP¥441.00m0.014%
$ 9.4m
Iwaaki Taniguchi
Senior Executive Officer2.5yrsno data0.00061%
$ 423.0k
Hitoshi Iikura
Executive VP2.5yrsno data0.00049%
$ 339.8k
Arnold Levine
Member of the International Advisory Councilno datano datano data
Osamu Nagayama
Honorary Chairman & Senior Advisor6.5yrsJP¥211.00mno data
Franz Humer
Member of the International Advisory Councilno datano datano data
Victor Halberstadt
Member of the International Advisory Councilno datano datano data
William Burns
Member of the International Advisory Councilno datano datano data
Henry Nordhoff
Chairman of the International Advisory Councilno datano datano data
Fumio Tateishi
Outside Independent Director3.5yrsno datano data
Andrew von Eschenbach
Member of the International Advisory Councilno datano datano data
Teresa A. Graham
Non-Executive Director3.5yrsno datano data
3.5yrs
Average Tenure
78yo
Average Age

Experienced Board: CHGC.Y's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/09 15:01
End of Day Share Price 2026/09/09 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chugai Pharmaceutical Co., Ltd. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Miki SogiBernstein
Koichi MameganoBofA Global Research